On December 13th, Gloronghui reported that CSPC PHARMA (01093.HK) announced that the group has entered into an exclusive licensing agreement with BeiGene Switzerland GmbH ("BEIGENE") for the Group's novel methionine adenosyltransferase 2A (MAT2A) inhibitor (SYH2039), as well as for the development, manufacturing, and commercialization of any Pharmaceuticals composed of or containing this compound on a Global basis.
According to the agreement and in accordance with its terms and conditions, the Group agrees to grant BEIGENE exclusive rights to develop, manufacture, and commercialize this compound and the product on a Global scale. The Group will receive a total of $0.15 billion in upfront payments and is entitled to receive up to $0.135 billion in potential development milestone payments and up to $1.55 billion in potential sales milestone payments, as well as tiered sales royalties calculated based on the annual net sales of the product.